eCite Digital Repository

PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation

Citation

Luinstra, M and Naunton, M and Peterson, GM and Bereznicki, L, PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation, Journal of Clinical Pharmacy and Therapeutics, 35, (2) pp. 213-217. ISSN 0269-4727 (2010) [Refereed Article]


Preview
PDF
Restricted - Request a copy
64Kb
  

Copyright Statement

The definitive published version is available online at: http://interscience.wiley.com

DOI: doi:10.1111/j.1365-2710.2009.01089.x

Abstract

Background/Aims: Antiplatelet therapy with aspirin and clopidogrel is an important component of the management of acute coronary syndrome, but it also increases the risk of bleeding. There are no formal guidelines about the use of a proton pump inhibitor (PPI) for gastroprotection in patients on clopidogrel. This study assessed how many patients in the Royal Darwin Hospital (RDH) and the Royal Hobart Hospital (RHH) prescribed clopidogrel and at risk of bleeding were co-prescribed PPIs. Methods: We conducted a retrospective cohort study using a pharmacy database to select all patients commenced on clopidogrel in a 1-year period. We identified all patients newly prescribed clopidogrel and determined the proportion that had a risk factor for bleeding and also received a PPI. We also assessed the effect of the use of PPIs on the number of reported bleeds. Results: The final study cohort consisted of 385 patients who had been newly prescribed clopidogrel. Of all patients discharged on clopidogrel, 95·6% (368/385) had ≥1 risk factor for bleeding. One hundred and twenty-eight of these patients [128/368, (34·8%)] were discharged on a PPI. Patients on dual antiplatelet therapy with an additional risk factor for bleeding and not discharged on a PPI were more likely to develop a major bleed than patients on dual antiplatelet therapy without a risk factor for bleeding not discharged on a PPI (11·1% vs. 1·8%; P < 0·01). Patients on dual antiplatelet therapy with an additional risk factor for bleeding not discharged on a PPI had a higher probability (borderline significance) of major bleeding, compared with patients on dual antiplatelet therapy with an additional risk factor for bleeding discharged on a PPI [PPI: 1/60, (1·7%) vs. no PPI: 6/54, (11·1%); P = 0·05]. Conclusions: Our results indicate that PPIs may only lower the probability of major bleeding in patients treated with dual antiplatelet therapy, who possess additional risk factor(s) for bleeding.

Item Details

Item Type:Refereed Article
Keywords:Antiplatelet therapy, aspirin, bleeding, clopidogrel, PPI
Research Division:Medical and Health Sciences
Research Group:Pharmacology and Pharmaceutical Sciences
Research Field:Pharmaceutical Sciences
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Blood Disorders
Author:Peterson, GM (Professor Gregory Peterson)
Author:Bereznicki, L (Professor Luke Bereznicki)
ID Code:64159
Year Published:2010
Web of Science® Times Cited:12
Deposited By:Pharmacy
Deposited On:2010-07-01
Last Modified:2011-04-24
Downloads:3 View Download Statistics

Repository Staff Only: item control page